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Aim: the aim of this study was to compare a photobiomodula-
tion device (Bioptron™) used as light therapy and Benzodiaz-
epines (BDZ) in burning mouth syndrome (BMS) treatment.
Methods: clinical and demographical data of 43 patients with 
a clinical diagnosis of BMS were randomized in two split 
groups. Group A was treated with Bioptron™ light therapy, 
whereas group B was treated with BDZ. Visual Analogue Scale 
(VAS) was used to assess the therapeutic effects of the given 
treatments in both groups. Outcomes were recorded at the be-
ginning of the treatment (t0) and at the end (tf).
Results: reduction of VAS was recorded in both groups with a 
significant improvement (p < 0.05). In Group A, the VAS de-
creased significantly (t0: 7.07: tf: 4.64). Also, in group B, mean 
VAS decreased significantly from 7.52 to 6.41. This study does 
not show a statistically significant difference between the two 
therapies (P = 0.064; p > 0.05).
Conclusion: results of the present study showed that both 
treatment were effective in reducing the patient-perceived pain 
and discomfort, although Bioptron™ light treatment showed a 
slightly bigger reduction in VAS points. As Bioptron™ light 
therapy has no known side-effects, and is a non-invasive pro-
cedure, this can allow for management of BMS patients in 
which customary medicaments with BZD may not be feasible. 
Further studies may focus on using light therapy and pharma-
ceuticals in combination, to try and understand if they may 
work better together in helping BMS patients.
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Aim: the ameloblastoma is the most frequent odontogenic tu-
mor. Despite its benign nature, the local aggressiveness and a 
high recurrence rate characterize some entities. Literature da-
ta suggest the BRAF V600E mutation is involved in 46-82% of 
ameloblastomas, offering a biological rationale for developing 
new therapeutic strategies. The study aims to evaluate the 
correlations between the presence of BRAF V600E mutation 
and the clinicopathological data in a cohort of ameloblastoma 
patients.
Methods: 50 ameloblastomas were subjected to immunohis-
tochemical analysis using VENTANA anti-BRAFV600E Mouse 
Monoclonal Primary Antibody. A uniform, cytoplasmic staining 
of viable tumor cells was considered as “positive” staining. Dif-
ferences among ameloblastoma groups were established by 
Chi-square and Mann-Whitney tests. A p-value < 0.05 was ac-
cepted as significant.
Results: the 46% of ameloblastomas harbored the BRAF V600E 
mutation. Its presence was significantly associated with the man-
dibular site (l = 0.0004) and unicystic histotype (l = 00383). All 
BRAF unicystic ameloblastomas arose in the mandible (l < 
0.0001). There was a trend between the presence of BRAF and 
the late onset of recurrent (l = 0.0521), without reaching a signifi-
cance difference in term of disease-free survival time.
Conclusion: our results suggest the MAP-kinase pathway 
could contribute on ameloblastic tumorigenesis. Moreover, 
they could indicate the anatomical specificity of the driving 
mutations of mandibular tumors, providing a biological ration-
al for developing new targeted therapies.
